Worth reading
38Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
990
¥10,000Wording
Avoiding a definitive answer
How definitive the wording is.Agreements reached under this partnership
Not a business alliance (services agreement concerning a specific research and development theme)Details of the alliance
- 1
Provision of the Company’s DDS aptamer technology for the counterparty’s technology evaluation
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
About the partner
Business DescriptionPharmaceutical company
LocationJapan (details undisclosed)
Impact on Business Performance
The impact of this agreement has already been incorporated into the earnings forecast for the fiscal year ending March 2027. The Company expects to receive ¥9.9 million in consideration.
Contract Date17 June 2026
| Item | Details |
|---|---|
| Alliance partner's business activities | Pharmaceutical company |
| Alliance partner's location | Japan (details undisclosed) |
| Type of alliance | Not a business alliance (services agreement concerning a specific research and development theme) |
| Details of the alliance | Provision of the Company’s DDS aptamer technology for the counterparty’s technology evaluation |
| Contract Date | 17 June 2026 |
| Impact on Business Performance | The impact of this agreement has already been incorporated into the earnings forecast for the fiscal year ending March 2027. The Company expects to receive ¥9.9 million in consideration. |
Items this document does not state (17)
Name of alliance partnerAlliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The counterparty will evaluate the Company’s DDS aptamer technology.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.